Optimizing systemic therapy selection in metastatic colorectal cancer.

Abstract excerpt

For metastatic colorectal cancer, many effective agents can be incorporated into multiple lines of therapy across the nearly 3-year continuum of treatment. Emphasis should be on using all the recommended agents, with extended duration of anti-vascular endothelial growth factor treatment, and on identifying patients with any mutation in the RAS pathway. Chemotherapy plus bevacizumab or an epidermal growth factor...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Angiogenesis Inhibitors
• Share to Antineoplastic Agents
• Share to Antineoplastic Combined Chemotherapy Protocols